Can a better lead clamp improve deep brain stimulation? Marshall University is building one to find out
What happens when a deep brain stimulation lead shifts by a millimeter during surgery? For conditions like Parkinson's disease and essential tremor, where the therapeutic target is a structure buried deep in the brain with tolerances measured in fractions of millimeters, even a small displacement can mean the difference between symptom relief and a failed procedure. That question has driven neurosurgeon Heather Pinckard-Dover to rethink one of the most basic tools in DBS surgery: the mechanism that holds the lead in place.
The fixation problem
Deep brain stimulation is a neurosurgical procedure in which thin electrical leads are implanted into precise brain targets and connected to a pulse generator that delivers continuous electrical stimulation. It is used to treat Parkinson's disease, essential tremor, dystonia, and, increasingly, other neurological and psychiatric conditions. The procedure's effectiveness depends entirely on accurate lead placement.
Current fixation systems are designed to stabilize leads once they reach their target. They work. But Pinckard-Dover, an associate professor of neurosurgery at Marshall University's Joan C. Edwards School of Medicine, saw room for improvement. After repeated discussions in the operating room about limitations in existing fixation methods, she recognized an opportunity to design something that could better support both surgical precision and workflow efficiency.
The specifics of the design remain confidential - the project is in early prototype development, and the intellectual property is being carefully managed. What is public is the collaboration: Marshall University, Marshall Health Network, and Intermed Labs, a medical technology commercialization partner, are jointly developing the device under the working name DBS Lead Lock.
From operating room to manufacturing lab
Initial prototypes are being built at the Marshall Advanced Manufacturing Center (MAMC), bringing together Pinckard-Dover's clinical insight, engineering capabilities, and commercialization strategy. The model is explicitly clinician-driven: the person who identified the problem in surgery is leading the solution's development.
Ashok Aggarwal, co-founder of Intermed Labs, described this as the way medical innovation should work: starting with a clinician who experiences a problem firsthand, then building around that insight with engineering and business resources.
Context in the DBS landscape
DBS technology has advanced considerably since its introduction in the late 1990s. Modern systems feature directional leads that can steer stimulation toward specific neural targets, rechargeable pulse generators, and adaptive algorithms that adjust stimulation in response to brain signals. The leads themselves have become more sophisticated.
But the mechanical infrastructure of surgery - the physical act of placing and securing a lead in the brain - has received less attention from the innovation pipeline. Lead fixation is one of those unsexy but critical components where incremental improvements could have meaningful clinical impact.
The DBS market is dominated by a small number of large medical device companies. For a university-based startup to enter this space, the device would need to demonstrate clear advantages in surgical precision, workflow improvement, or patient outcomes - and navigate the regulatory pathway for a new surgical tool.
Early stage, uncertain path
The DBS Lead Lock is a prototype in development, not a validated medical device. No clinical testing has been performed. No regulatory submissions have been filed. The project represents a hypothesis: that improvements in lead fixation could enhance positioning stability and streamline surgical workflow. Whether the prototype bears out that hypothesis, and whether it can be manufactured at scale, tested in clinical settings, and commercialized, are all open questions.
What the initiative does represent is an institutional bet by Marshall University on translational research - bridging the gap between clinical need and commercial product in a region not traditionally associated with medical device innovation. Whether it produces a product that reaches operating rooms remains to be seen. But the model of clinician-identified problems driving engineering solutions is sound, and the collaboration structure is designed to take the concept from observation to evaluation systematically.